<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430610</url>
  </required_header>
  <id_info>
    <org_study_id>Uterine Cerv cancer-IRE-01</org_study_id>
    <nct_id>NCT02430610</nct_id>
  </id_info>
  <brief_title>Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms</brief_title>
  <acronym>IRE</acronym>
  <official_title>Irreversible Electroporation(IRE) For Unresectable Uterine Cervical Neoplasms: Phase I and Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of irreversible
      electroporation (IRE) for unresectable Uterine Cervical Neoplasms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with unresectable Uterine Cervical Neoplasms adapted to enrolled
      criteria, this study will document for the first time the safety and the short and long term
      efficacy of percutaneous IRE for unresectable Uterine Cervical Neoplasms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse events</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voltage (A minimum and maximum range of voltage for safe and effective IRE)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A minimum and maximum range of voltage for safe and effective IRE</measure>
    <time_frame>3 months</time_frame>
    <description>A minimum and maximum range of voltage for safe and effective IRE will be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress free disease (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Patients will be followed for 36 months after IRE for OS analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>IRE Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irreversible electroporation for Unresectable Uterine Cervical Neoplasms</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irreversible electroporation (IRE)</intervention_name>
    <description>Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.</description>
    <arm_group_label>IRE Group</arm_group_label>
    <other_name>NanoKnife</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NanoKnife</intervention_name>
    <arm_group_label>IRE Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uterine Cervical Neoplasms diagnosed by positive biopsy or non-invasive criteria,

          -  Not suitable for surgical resection,

          -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,

          -  A prothrombin time ratio &gt; 50%,

          -  Platelet count &gt; 80x10^9/L,

          -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days
             prior to and seven days post NanoKnife procedure,

          -  Able to comprehend and willing to sign the written informed consent form (ICF),

          -  Have a life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,

          -  Any active implanted device (eg Pacemaker),

          -  Women who are pregnant or women of child-bearing potential who are not using an
             acceptable method of contraception,

          -  Have received treatment with an investigational agent/ procedure within 30 days prior
             to treatment with the NanoKnifeâ„¢ LEDC System,

          -  Are in the opinion of the Investigator unable to comply with the visit schedule and
             protocol evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lizhi Niu, PhD</last_name>
    <email>niuboshi@fudahospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biological treatment center in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Jibing, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>March 27, 2016</last_update_submitted>
  <last_update_submitted_qc>March 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>irreversible electroporation</keyword>
  <keyword>Unresectable Uterine Cervical Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

